Abstract
Response rates of up to 89% have been achieved in patients with advanced ovarian cancer who received novel antineoplastic therapy combinations. Antitumour activity has also been demonstrated by an immunotherapeutic vaccine, leading to the long-term stabilisation of disease in many patients. These promising new approaches to treating advanced ovarian cancer were described at the 6th International Congress on Anti-Cancer Treatment [ Paris, France; February 1996 ].
Rights and permissions
About this article
Cite this article
Prescott, L. High response rates with new treatments for advanced ovarian cancer. Inpharma Wkly. 1027, 3–4 (1996). https://doi.org/10.2165/00128413-199610270-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-199610270-00004